Loading clinical trials...
Loading clinical trials...
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate that the closed loop algorithm that is built into the 670G insulin pump is safe as part of the overall system.
The study will proceed as follows: Run-in Period: A total of up to 150 subjects (age 14 - 75) will be enrolled at up to 10 investigational centers (9 in the US, 1 in the Europe, Middle East and Africa (EMEA) region) in order to reach 100 subjects who will complete the HCL study. The 2-week run-in period will be used to allow subjects to become familiar with new study devices. During the two week run-in period subjects will be using the Study Pump (670G) with the Sensor Augmented Pump function only activated (i.e. SmartGuard OFF and HCL OFF). Study Period - At Home: Following the two week run-in period using the Study Pump (670G), all subjects will participate in a 3-month study period. Subjects will be required to have a companion with them during the night for the duration of the study period. Companions will need to be under the same roof, but not necessarily in the same bedroom. During the Hotel stay where subjects are monitored closely, the presence of a companion is not necessary. Study Period - Hotel Study Subjects will participate in a Hotel study (6 days, 5 nights), with the remainder of the study period to be spent at home. All subjects will undergo daytime and nighttime Frequent Sample Testing (FST) for approximately 24 hours during the Hotel study with YSI or i-STAT® used as a reference value. With respect to meals, subjects will be allowed to eat as they normally do. Continued Access Program Subjects will be given the opportunity to extend use of their study devices for a period of 3 years. If subjects choose to participate in the continuation period, they will retain the study devices at the end of study period visit or receive them back in the event they have been returned to study staff already. During the continuation period, subjects will come in for office visits every 3 months. At each of the quarterly visits, subjects will be asked about the occurrence of adverse events and device complaints.
Age
14 - 75 years
Sex
ALL
Healthy Volunteers
No
AMCR Institute
Escondido, California, United States
Stanford University Medical Center
Palo Alto, California, United States
Barbara Davis Center for Childhood Diabetes (Adult)
Aurora, Colorado, United States
Barbara Davis Center for Childhood Diabetes (Pediatric)
Aurora, Colorado, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Atlanta Diabetes Associates
Atlanta, Georgia, United States
Park Nicollet Clinic-International Diabetes Center - Adult and Pediatric
Minneapolis, Minnesota, United States
University of Virginia
Charlottesville, Virginia, United States
Rainer Clinical Research Center
Renton, Washington, United States
Institute of Endocrinology, Sheba Medical Center
Tel Aviv, Israel
Start Date
June 1, 2015
Primary Completion Date
March 1, 2016
Completion Date
October 1, 2018
Last Updated
April 16, 2019
124
ACTUAL participants
Insulin Pump
DEVICE
Lead Sponsor
Medtronic Diabetes
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07455994